Acelyrin (SLRN) Reiterates Benefits of Value-Maximizing Combination with Alumis (ALMS) May 1, 2025 01:31PM
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis May 1, 2025 01:30PM
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger Mar 4, 2025 09:00AM
Acelyrin (SLRN) Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences Feb 21, 2025 07:21AM
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences Feb 20, 2025 09:00PM